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ABSTRACT Production of interleukin 1 (IL-1) by leuke-
mic cells was studied in 13 cases of acute myeloid leukemia.
Intracytoplasmic immunofluorescence studies showed that the
cells invariably contained the cytokine. Endogenous labeling
studies demonstrated that acute myeloid leukemia cells pro-
duced either only the 33-kDa propeptide or both the propeptide
and the 17-kDa mature form of IL-1l8. The 33-kDa propeptide
IL-ia was always produced but was less frequently released.
Involvement of IL-1 in leukemic cell growth was investigated
using two antibodies specific for IL-1 subtypes, which inhibited
spontaneous cell proliferation in the six cases studied. After
acid treatment of the cells, a surface receptor for IL-1 could be
demonstrated, which mediated 12'I-labeled IL-i-specific up-
take by leukemic cells. Furthermore, recombinant IL-la or
IL-1i8 induced significant cell proliferation in 10 of 12 cases.
The above findings were uncorrelated with the cytologic type
(French-American-British classification) of leukemia. Our
studies suggest that IL-i may act as an autocrine growth factor
in most cases of acute myeloid leukemia.
Acute myeloid leukemia (AML) is a malignant process
characterized by abnormal growth and maturational arrest of
myeloid precursor cells. These abnormalities may be related
to the escape by leukemic cells from normal genetic control
mechanisms. Alternatively, AML cells may become inde-
pendent from the supply of exogenous growth factors, which
are necessary for optimal proliferation and differentiation of
their normal counterparts. This second mechanism could be
due to the ability ofAML cells to synthesize and respond to
growth factors. An autocrine secretion ofgrowth factors may
be operational in many malignancies (1). Recently leukemic
cells from some AML patients have been reported to con-
stitutively produce granulocyte macrophage-colony stimu-
lating factor (2, 3), one hormone that stimulates immature
myeloid cell proliferation and differentiation (4).
We have shown previously that cells from some AML
patients release large amounts of interleukin 1 (IL-1) in vitro
(5). This latter feature was related to the presence in vivo of
coagulation abnormalities, such as the diffuse intravascular
coagulation syndrome. Because IL-1 appears to promote the
growth of several cell types, we suggested that IL-1 could
operate as an autocrine growth factor-at least for some
AML clones. In this study, we demonstrate that cells from all
AML patients studied can produce IL-1. We also show that
anti-IL-1 antibodies can modulate the spontaneous prolifer-
ation of leukemic cells and that exogenous human recombi-
nant (r) IL-la or IL-1f3 interacts specifically with leukemic
cells and enhances their growth ability.
MATERIALS AND METHODS
Patients. Thirteen patients with AML were randomly
selected; diagnosis of AML was based on clinical, morpho-
logical, and cytochemical criteria, according to the French-
American-British classification (6). All patients were studied
before any treatment, and informed consent was obtained.
Reagents. Purified recombinant IL-la and IL-1l8 were
obtained as described (7, 8). The specific activity of both was
1.3 x i07 half-maximal units per mg in the thymocyte costim-
ulation assay. Recombinant tumor necrosis factor (TNF) and
interferon y (IFN-'y), specific activity 9.6 x 106 units/mg in the
L929 cytotoxicity assay and 2.1 x 107 National Institutes of
Health reference units per mg, respectively, were gifts from
Biogen (Geneva). Neutralizing antisera against rIL-la and
rIL-i,/ were obtained in rabbits. These sera contained 107 and
0.5 x 106 neutralizing units per ml, respectively, and did not
affect the proliferation of continuous IL-2-dependent normal
T-cell lines when used at a final dilution of 1:50.
Separation and Culture of Leukemic Cells. Leukemic cells
were isolated by Ficoll/Hypaque (Pharmacia, Prodotti Gi-
anni, Milan) density gradients as described (5). Cells were
washed and resuspended in RPMI 1640 (Flow Laboratories,
Milan) supplemented with 2 mM L-glutamine, 100 units of
penicillin per ml, 100 gg of streptomycin per ml, 100 ,ug of
polymixin B per ml (hereafter referred to as complete medium,
CM), and 10o fetal calf serum (Flow). After separation,
cytocentrifuged smears were stained with May-Grunwald-
Giemsa and scored for atypical cells. When necessary, cell
suspensions were depleted ofnormal monocytes by incubation
at 37°C for 1 hr in plastic Petri dishes and depleted of T cells
by rosetting with neuraminidase-treated sheep erythrocytes.
All suspensions always contained >95% malignant cells.
To obtain conditioned medium, cells were cultured in
complete medium/fetal calf serum at a concentration of 1 x
106 cells per ml for 48 hr. For the cell proliferation studies,
different concentrations of leukemic cells from 1 x 104 cells
per ml to 2.5 x 105 cells per ml were incubated in 96-well
microtiter plates for 48 hr with or without rIL-la or rIL-1p3,
rTNF, or rIFN-y at 5 ng/ml and with neutralizing antibodies
anti-IL-la, anti-IL-1,8, or preimmune rabbit serum as con-
trol. Different dilutions, 1:4-1:32, of IL-1-containing leuke-
mic cell supernatants were tested in the same culture condi-
tions. Cultures were treated with 0.5 ,uCi of [3H]thymidine
([3H]Thd) (specific activity 25 Ci/mmol; 1 Ci = 37 GBq;
Amersham, Prodotti Gianni) 18 hr before harvesting, and the
radioactivity was determined in a liquid scintillation counter
(Beckman Analytical, Milan).
Abbreviations: IL-1, interleukin 1; AML, acute myeloid leukemia;
TNF, tumor necrosis factor; IFN-y, interferon y; r, recombinant;[3H]Thd, [3H]thymidine.
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Evaluation of IL-1 Production. The IL-1 produced by
leukemic cells was assessed by intracytoplasmic immuno-
fluorescence, endogenous labeling and immunoprecipitation
experiments, and measurement of biological activity.
Immunofluorescence was performed essentially as de-
scribed by Bayne et al. (9). Briefly, freshly drawn leukemic
cells were cytocentrifuged, fixed in 2% (wt/vol) paraform-
aldehyde, and permeabilized with 0.1% Triton X-100; the
cells were then incubated with a 1:50 dilution of anti-IL-1
antiserum or preimmune rabbit serum as control, washed,
and stained with fluorescein isothiocyanate-conjugated goat
anti-rabbit antiserum (Cappel Laboratories, BCI Human,
Milan) at a final dilution of 1: 100. Specimens were examined
either by conventional microscope or by a confocal scanning
laser microscope developed by B. Amos and J. White
(Medical Research Council Laboratory of Molecular Biol-
ogy, Cambridge, U.K.).
IL-1 activity in culture supernatants was assayed as de-
scribed (10) by the thymocyte costimulation assay with rIL-
1,3 as standard.
Endogenous labeling and immunoprecipitation studies
were performed as described (11). Freshly drawn leukemic
cells were incubated at 107 cells per ml for 6 hr in methionine-
free RPMI 1640 medium (Flow) supplemented with 5%
dialyzed fetal calf serum in the presence of [35S]methionine at
100 ,uCi/ml (specific activity, 800 Ci/mmol, NEN/DuPont
Italia, Firenze). Cells were then centrifuged, washed, and
lysed in phosphate-buffered saline with 0.25% Nonidet P-40.
Samples of both cell lysates and supernatants were immu-
noprecipitated with 5 ,ul of anti-IL-la or anti-IL-1i3 antisera
or of preimmune rabbit serum as control, followed by 50 ,1
of protein A-Sepharose CL-4B (Pharmacia). Immunopre-
cipitates were extensively washed, eluted by boiling in
Laemmli stacking buffer (12) containing 5% (vol/vol) 2-
mercaptoethanol, run on 12% NaDodSO4/PAGE, and auto-
radiographed.
Radioiodination of rIL-la. rIL-1a was radioiodinated using
the method reported by Lowenthal and MacDonald (13). The
specific activity was 0.5 x 105 cpm/ng. The material pro-
duced a single band of 17 kDa in aNaDodSO4/PAGE analysis
and retained its biological activity.
Surface Binding and Uptake of 125I-Labeled IL-la. Binding
experiments were performed at 4°C for 2 hr as described (13,
14). Cells were incubated in Hepes-buffered RPMI 1640
medium at pH 3.0, washed, and resuspended in medium at
pH 7.4 supplemented with 0.02% sodium azide and 0.5%
bovine serum albumin. Leukemic cells (3-6 x 106) were
incubated with different concentrations (10 pM-3 nM) of
125I-labeled IL-la, with or without a 100-fold excess of un-
labeled IL-la. Free radioactivity was separated from bound
radioactivity by centrifugation through an oil gradient. The
same procedures were also applied to either the murine T-cell
line EL4 or purified normal T lymphocytes stimulated for 16
hr with phorbol myristate acetate. Data were analyzed by a
scientific data analysis program (Enzfitter-Biosoft, Cam-
bridge, U.K.) to determine the Kd of the reaction and the
number of receptor molecules per cell.
For determination of IL-1 uptake, 3 x 106 cells were
incubated for 2-4 hr at 37°C with 0.5 or 1 nM 125I-labeled IL-1
with or without excess unlabeled IL-1. The suspensions were
then centrifuged, the supernatants were harvested, and the
cells were washed three times with phosphate-buffered saline
and lysed in Nonidet P-40 as above. Aliquots of both
supernatants and cell lysates were dissolved in the scintilla-
tion mixture and directly counted or treated overnight with
10% (vol/vol) trichloroacetic acid at 4°C, neutralized in
Laemmli stacking buffer, and analyzed by NaDodSO4/
PAGE as above.
RESULTS
IL-1 Production by AML Cells. Cells from 13 randomly
selected AML patients were analyzed for the release of IL-1
activity in culture supernatants by use of the thymocyte
costimulation assay and for intracellular IL-1 by cytoplasmic
immunofluorescence with anti-IL-la or anti-IL-l1, monospe-
cific antibodies. These analyses demonstrated that cells from
10 of the 13 cases studied released IL-1 activity spontane-
ously (Table 1) after a 48-hr culture period. By contrast,
every case showed a high proportion of cells (.80%) con-
taining detectable IL-1 molecules (Fig. 1) either before or
after the culture. In particular, two-color immunofluores-
cence indicated that both a and P molecular forms of IL-1
were present within the same leukemic cell, although differ-
ences in staining intensities were often seen (data not shown).
To investigate in more detail the molecular pattern of IL-1
production and release, leukemic cells from eight patients
were endogenously labeled with [35S]methionine for 6 hr.
Both cell lysates and supernatants were subsequently immu-
noprecipitated with antibodies to IL-la or IL-1,3, and the
immunoprecipitates were analyzed by NaDodSO4/PAGE.
Results of these experiments demonstrated that cells from all
patients synthesized the 33-kDa precursor molecule of both
IL-la and IL-183, although the former was less abundant (Fig.
2). The 33-kDa pro-IL-1p, but not pro-IL-la, was consis-
tently released in the culture supernatant. By contrast, the
17-kDa mature IL-1,3 was immunoprecipitated from the
culture supernatants of five cases of the eight studied in
which IL-1 activity was also detected.
Role of IL-1 in AML Cell Proliferation. That cells from all
AML patients produced IL-1 suggested that this cytokine
could be involved in some functions of the leukemic cells.
Because IL-1 has been demonstrated to promote cell growth
in several systems (15), the role of IL-1 for AML cell
proliferation was evaluated. Cells (1 x 105) from 10 patients
were cultured for 48 hr with or without neutralizing anti-
IL-ia or anti-IL-il/3 antibodies, and their proliferative activity
was evaluated. In all cases the anti-IL-1 antibodies could
inhibit the spontaneous [3H]Thd uptake in a dose-dependent
fashion, although to a different extent (Table 2). This phe-
nomenon was independent of the level of spontaneous cell
proliferation, which varied greatly in the different AML
patients. Interestingly, anti-IL-la antibodies were less effec-
tive than anti-IL-1,3 in inhibiting cell proliferation. This
finding is consistent with the poor production of IL-la, as
determined by the endogenous labeling experiments de-
Table 1. IL-1 activity released by AML cells
Patients (cell type)
C.A.
B.G.
M.R.
F.I.
D.M.
B.E.
S.I.
P.A.
Z.D.
B.S.
M.M.
B.T.
C.L.
(Ml)
(M4)
(M4)
(M2)
(M2)
(M2)
(M5)
(M5)
(M2)
(M5)
(M2)
(M2)
(Ml)
IL-1 activity, units/ml
56
140
65
136
47
80
168
21
24
28
AML cells were cultured at 1 x 106 cells per ml for 48 hr.
Supernatants were harvested and tested for IL-1 activity in the
thymocyte costimulation assay. The cytological types, according to
French-American-British classification (6), appear in parentheses.
For comparison, unstimulated or lipopolysaccharide-stimulated
monocytes from eight normal donors yielded under the same con-
ditions 20 ± 2 and 75 ± 11 units/ml, respectively.
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FIG. 1. Immunocytochemical detection of IL-1 in AML cells. Freshly drawn AML cells were fixed in 2% paraformaldehyde, permeabilized
by 0.1% Triton X-100, and stained with polyclonal rabbit anti-IL-1 antibodies followed by fluorescein-conjugated goat anti-rabbit antibodies.
The cells were examined by a confocal scanning laser microscope.
scribed above. An intriguing observation is that anti-IL-1
antibodies also could inhibit the cell growth in patient M.M.,
whose cells did not release detectable IL-1 (Table 2).
These results suggested that IL-1 was involved in AML cell
proliferation as an autocrine growth factor. Further support
for this thesis came from the observation that IL-i-containing
supernatants from AML cells cultured at high density could
elicit a significant proliferative response of the cells, cultured
at lower density, from the same or another AML patient.
Table 3 shows the results of two selected experiments.
A B
1 2 3 4 1 2 3 4
33* _- ak _
17*4
ci s ci s ci s Ci s
anti-a anti-[3 anti-a anti-13
FIG. 2. Different patterns of IL-1 production by cells from AML
cases. Leukemic cells were endogenously labeled with [35S]methio-
nine for 6 hr. Cell lysates (cl) and supernatants (s) were immuno-
precipitated with anti-IL-la (lanes 1 and 2) or anti-IL-1l3 (lanes 3 and
4) polyclonal antibodies, and the immunoprecipitates were analyzed
by NaDodSO4/PAGE. Preimmune sera failed to precipitate any
detectable material. Two representative experiments (A and B) of
eight performed are shown. Figures at left represent kDa.
Supernatants obtained from 48-hr cultures of 1 x 106 cells per
ml from patients M.R., B.G., and F.I., tested against 1 x i05
cells per ml from patients M.R. and M.M., induced a signif-
icant proliferative response. The table also shows that the
[3H]Thd incorporation induced by the supernatants was
markedly reduced by anti-IL-1 antibodies.
Proliferative Response ofAML Cells to Exogenous IL-1. We
further investigated whether or not exogenous IL-1 could
substitute for the autocrine growth factor of the supernatant.
AML cells were cultured with or without rIL-la or rIL-13 or
other recombinant cytokines, such as TNF and IFN-y as
control. Table 4 shows that both rIL-la and rIL-113 could
Table 2. Effect of anti-IL-la and anti-IL-1,8 antibodies on AML
cell proliferation
[3H]Thd incorporation by cells from
patient, cpm
Added serum M.R. B.G. MM.
None 3845 11,474 2040
anti-IL-la
1:50 2004 8,875 1875
1:250 2850 9,436 1920
1:1000 3475 11,314 2100
anti-IL-1,8
1:50 950 3,796 680
1:250 1250 4,235 920
1:1000 2947 10,384 1820
Control (1:50) 3780 10,990 2129
AML cells were cultured at 5 x 105 cells/ml for 48 hr with or
without anti-IL-la, anti-IL-13, or control serum. Results of three
representative experiments of six performed are shown. Data are
expressed as mean of triplicate cultures; SD was always <10%.
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Table 3. Proliferative activity of AML cells induced by AML
cell supernatants
[3H]Thd incorporation, cpm
M.R. M.M.
Stimulus None anti-IL-1$ None anti-IL-1*
None 1,450 456 560 298
Supernatant
M.R. 7,850 2647 4,880 1498
B.G. 8,950 3879 7,540 1579
F.I. 10,480 3900 15,640 2968
AML cells from patients M.R. and M.M. were cultured at 1 x 105
cells per ml for 48 hr with or withoutAML cell supernatants (1:4 final
dilution). Data are shown as the mean of triplicate cultures; SD was
<10%.
*Anti-IL-la and anti-IL-1,8 antisera were added at 1:100 final
dilution. Controls with the same amounts of preimmune rabbit
serum consistently failed to show any toxic effect.
induce cell growth in 10 of 12 cases, with a stimulation index
ranging from 3 to 25. Anti-IL-i antibodies speciflically
blocked the phenomenon, and rTNF or rIFN-y, as controls,
failed to promote cell proliferation (data not shown). In most
cases the supply of exogenous rIL-la or rIL-1P allowed the
establishment of continuous cell lines that grew for >2 mo.
Interestingly, different cell concentrations had to be tested in
each AML case to detect proliferation in response to the
exogenous factor-possibly due to interference of the endog-
enously available IL-1. The response to exogenous IL-1 was
neither related to the presence or absence of IL-1 activity in
the cell supernatants nor to the level of spontaneous cell
proliferation (see also Table 1 for comparison).
IL-1 Binding and Uptake by AML Cells. To demonstrate
directly a specific interaction between IL-1 and its surface
receptors, we performed binding experiments with 125I-
labeled rIL-1 using cells from several AML cases. Widely
accepted procedures (13, 14) consistently failed to show
specific receptors on this particular cell type. However, we
reasoned that the endogenous ligand could be occupying the
receptors; we therefore incubated the cells in acidic buffer to
remove any such ligand. Fig. 3 shows that after acid treat-
ment specific binding occurred. Kd of the reaction was =2 x
10-10 M and, from the Scatchard analysis of the data, we
calculated that an average number of 200 receptor molecules
per cell was expressed. We further tried to demonstrate IL-1
internalization by AML cells. Cells were incubated for 4 hr
at 370C with different concentrations of l25l-labeled rIL-1
Table 4. IL-1-induced proliferation of AML cells
[3H]Thd incorporation, cpm
Patient None rIL-la rIL-1/3
M.R.* 1,211 14,530 13,876
B.S.* 2,491 7,889 8,143
F.L.* 12,595 53,888 51,459
B.T.* 2,470 18,300 21,100
M.M.* 912 15,219 14,345
D.M.* 812 4,426 4,915
B.G.t 2,238 20,295 19,8%
Z.D.t 3,248 13,044 11,621
C.AJt 1,456 4,145 4,768
P.AJt 2,103 13,087 14,001
B.E.* 5,354 5,250 5,987
S.I.L* 1,314 1,544 1,654
AML cells were cultured in triplicate at 2.5 x 105 cells per ml (*)
or 1 x 105 cells per ml (t), or 1.25 x 104cells per ml (t) for 48 hr with
or without rIL-la (100 units/ml) or rIL-1.3 (100 units/ml). Data are
shown as mean of triplicate cultures; SD was <10%. Control cultures
with other recombinant factors (TNF, IFN-y) did not show any
significant increase in the spontaneous proliferation of AML cells.
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FiG. 3. 125I-labeled IL-1 surface binding. Cells (3 x 106) from
patient P.A. were incubated at 40C for 2 hr with different concen-
trations of 125I-labeled IL-la. The specific radioactivity of the
molecule was 5.1 x 104 cpm/ng. Specific binding was calculated by
subtracting the count of samples incubated with 100-fold excess of
unlabeled IL-la. Nonspecific binding was s25%. Comparable re-
sults were obtained in three different experiments with cells from
other AML patients.
with or without excess unlabeled rIL-1. At the end of the
incubation period, cells were washed, lysed, and aliquots
from cell lysates and supernatants were harvested for direct
counts, trichloroacetic acid precipitation, and gel analysis. A
specific uptake of 125I-labeled IL-1 was evident at 370C (Fig.
4) but not at 40C (data not shown). Further evidence came
from NaDodSO4/PAGE analysis, which showed that a dose-
dependent uptake of 125I-labeled IL-1 by the cells, as indi-
cated by a 17-kDa band, occurred when cells were incubated
with different amounts of 125I-labeled IL-1 without but not
with excess unlabeled rIL-1. Supernatants containing both
125I-labeled IL-1 and unlabeled IL-1 displayed more intense
bands in comparison with supernatants containing labeled
IL-1 only. It is noteworthy that no IL-1 degradation was seen
(data not shown).
DISCUSSION
We demonstrate that cells from AML patients invariably
produce IL-1, which in turn supports the proliferation of the
leukemic cells. This contention is supported by the following
experimental observations: (i) endogenous labeling studies
and immunofluorescence analysis show that either the 33-
kDa propeptide form of IL-1 or both the propeptide and the
17-kDa mature forms are synthesized by most cells from the
single leukemic clones; (ii) leukemic cells can recognize
specifically exogenous IL-1, as shown by binding and uptake
of radiolabeled IL-1 molecules; (iii) proliferation of AML
cells in culture is affected by anti-IL-i antibodies, and culture
supernatants containing IL-1 specifically increase the leuke-
mic cell growth. The latter phenomenon can be reproduced
MW 1 2 3 4 12 3 4
- mom
..
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FIG. 4. NaDodSO4/PAGE analysis of 125I-labeled IL-la present
in cell lysate and supernatant from AML cells incubated at 37TC for
4 hr without (lanes 1 and 2) or with (lanes 3 and 4) 100-fold excess of
unlabeled IL-la. 125I-labeled IL-la was used at concentrations of0.5
nM (lanes 1 and 4) or 1 nM (lanes 2 and 3).
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with the use of exogenous rIL-1. Altogether, these data
indicate that IL-1 acts as an autocrine growth factor for AML
cells. The evidence that cells from all AML cases actively
synthesize IL-1 suggests a general role for this cytokine in
leukemic cell proliferation. The observation that the cells
from all our cases produced IL-1 confirms and extends the
data reported by Griffin et al. (16), who showed easily
detectable IL-183 mRNA in cultured cells from 10 of 17 cases.
In this connection, it has recently been reported that only in
one of two cases of AML did cells produce IL-1 and in one
of five cases did IL-1 elicit a proliferative response (17).
These discrepancies are probably related to the more sensi-
tive experimental procedures used in our studies, such as the
endogenous labeling and immunofluorescence analyses for
IL-1 detection and the various cell concentrations used in the
proliferation assays. In our studies, cells displaying an active
spontaneous proliferation failed to respond to exogenous
IL-1 at the highest cell densities, and a response was
detectable only when cells were cultured at lower densities.
At high cell concentrations, the endogenously produced IL-1
may obscure the effects of the exogenous factor.
In our experiments, IL-la and IL-1p8 were equally effective
in promoting cell growth, a finding consistent with the
evidence that both molecules compete for the same receptor
(18-20). However, in most AML cases, IL-ifp was the
molecular form more abundantly produced, a finding that
could explain why anti-IL-ip antibodies were more effective
in inhibiting spontaneous cell growth. However, in those
cases in which IL-la was produced in significant amounts,
anti-IL-la antibodies profoundly affected cell proliferation.
AML cells were equipped with specific receptors that were
occupied by the endogenously produced IL-1. As in other
systems in which autocrine factors were involved (21, 22), acid
treatment could remove endogenous IL-1 and hence allow
analysis of the receptor molecule. Both the affinity and the
number of receptors were comparable to those reported for
other cell types. In particular, unlike the receptors for other
cytokines, a few hundred molecules were expressed on each
single cell. The efficient binding and utilization of endogenous
IL-1 after production could account for the absence of IL-1
activity in the supernatants of cells from the two cases studied
in which anti-IL-1 antibodies did affect cell proliferation.
Alternatively, leukemic cells could use the 33-kDa propeptide
form of IL-1,8 they consistently release, which is devoid of
biologic activity when tested on murine T cells (23).
Cells from two ofthe twelve patients studied, who were high
producers of IL-1, failed to respond to the exogenous factor at
any cell concentration tested. Again, an explanation could be
the production, even at low cell concentrations, ofendogenous
factor in amounts sufficient to sustain cell proliferation.
In our series, IL-1 involvement in cell proliferation was
shown for cells of different cytological types. This suggests
that an autocrine pathway is related to the malignant nature
of the cells, rather than being reminiscent of the physiological
behavior of normal myeloid counterparts. Alternatively, the
autocrine mechanisms of proliferation could have a wider
significance than that so far suspected.
Previously IL-1 was reportedly able to promote prolifera-
tion of several cell types such as, for example, T and B
lymphocytes, immature myeloid precursors, epidermal cells,
fibroblasts, etc. (15). The precise mechanisms underlying the
growth-promoting activity of IL-1 remain unclear. However,
data obtained from studies on the T-cell system, in which
IL-1 induces IL-2 and IL-2 receptor expression (24-27),
suggest that a single basic mechanism-i.e., induction of
growth factor or growth factor receptor expression is respon-
sible for the effect of IL-1 on cell proliferation. Support for
this hypothesis comes from recent evidence showing that
IL-1 synergizes with granulocyte colony-stimulating factor,
perhaps upregulating the expression of its receptor on normal
myeloid cell precursors (28), and that IL-1 can induce
granulocyte/macrophage colony-stimulating factor expres-
sion by endothelial cells (29). Because myeloid leukemic cells
produce and proliferate in response to granulocyte/macro-
phage colony-stimulating factor (2, 3), it seems possible that
IL-1 is part of a more complex autocrine loop.
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